Parabilis starts dose-ranging FAP study of zolucatetide

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/14/2026

1. DPZ
2. NVDA
3. DRS
4. GS
5. BAC
6. UNH
7. ORCL
8. AVAV
9. ACI
10. JPM

Go back to Parabilis starts dose-ranging FAP study of zolucatetide

Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous Polyposis

October 14, 2026 7:00 AM EDT

New dose-ranging cohort in FAP builds on compelling early clinical evidence observed with zolucatetide in patients with FAP and concomitant desmoid tumors

Zolucatetide directly inhibits -catenin:TCF, targeting the APC-mutation biology that drives precancerous adenomatous polyp formation in patients with FAP

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines (Nasdaq: PBLS), a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for patients with serious diseases by unlocking historically undruggable targets, today announced the initiation of a dose-ranging clinical cohort evaluating zolucatetide in patients with familial... More